Clinical Sales Specialist

Corcept Therapeutics stock jumps ahead of Q2 earnings. TIM BOHEN - UPDATED JUL. 29, 2026, 4:48 PM ET Corcept Therapeutics Incorporated stocks have been trading up by 17.18 percent following highly positive coverage of its clinical pipeline. Key takeaways for CORT traders. * Corcept Therapeutics set the date for its Q2 2026 earnings release and corporate update, plus a live conference call and webcast for traders to track. * The company reiterated its focus on cortisol modulation and its two FDA-approved drugs, Korlym and newly approved Lifyorli for platinum-resistant ovarian cancer. * A Form 4 SEC filing shows CFO Atabak Mokari sold 40,000 shares (about $3.5M) on 2026/07/15 and now directly holds 16,130 shares. * Another Form 4 filing flagged a separate change in beneficial ownership of Corcept Therapeutics shares by an insider or major holder. Live Update At 16:48:08 EDT: On Wednesday, July 29, 2026 Corcept Therapeutics Incorporated stock [NASDAQ: CORT] is trending up by 17.18%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. For active traders, CORT is acting like a high-priced biotech leader with momentum but also a rich valuation. The daily chart shows CORT grinding higher through July, with the stock climbing from the high-$80s to close near $93 on 2026/07/29 after several strong sessions. The intraday tape backs that up: CORT opened around $94.84, held a tight range most of the day, then exploded after hours with a spike through $110 on heavy volume, classic breakout behavior into a catalyst. Fundamentally, Corcept Therapeutics just printed quarterly revenue of about $165M, backed by a huge 98% gross margin. That is rare air. But net income was a loss of roughly $32M, thanks to heavy R&D and selling expenses. CORT still carries a lofty P/E above 130 and a price-to-sales ratio near 6.5, telling traders this is a growth story, not a value play. On the balance sheet, CORT looks clean: low debt, a current ratio around 2.9, solid cash and investments over $300M. That gives Corcept Therapeutics room to keep funding trials and the launch of Lifyorli. For traders, it means dilution risk is lower near term, but expectations into earnings are sky high. Why traders are watching CORT into earnings. Corcept Therapeutics just put a date on its Q2 2026 earnings release and corporate update, and that alone is putting CORT on more screens. An official call and webcast means a clear catalyst window, and the after-hours surge into the low-$110s shows traders are already positioning. When a stock ramps into earnings, it tells you the market expects strong commentary, not just from Korlym but from newly approved Lifyorli. CORT is no longer a one-drug story. Corcept Therapeutics now has two FDA-approved products, both tied to its cortisol modulation platform. That shift matters. Multi-product stories usually get richer multiples, and CORT is already priced aggressively. Traders will be locked in on any color around Lifyorli's early launch metrics in platinum-resistant ovarian cancer and on updates for advanced clinical trials in the pipeline. At the same time, insider activity is throwing a bit of shade on the party. A Form 4 shows CFO Atabak Mokari unloading 40,000 CORT shares, roughly $3.5M, on 2026/07/15, leaving him with 16,130 shares. Another Form 4 flagged a change in beneficial ownership by an insider or major holder. For short-term trading, that combo often acts as a sentiment overhang. Insider selling does not prove trouble at Corcept Therapeutics, but active Form 4 traffic near an earnings date tells traders to listen very carefully to guidance and tone. If CORT delivers strong numbers and a confident update on Lifyorli, those sales may get shrugged off. If the call sounds cautious, traders may treat the insider moves as an early warning and fade the post-earnings pop. Conclusion. CORT is stepping into its Q2 2026 earnings with momentum, a fresh all-time high zone, and a stronger product story than it had a year ago. Corcept Therapeutics has real revenue, elite margins, and a clean balance sheet, yet it is still trading like a high-expectation growth name with a triple-digit P/E. That mix makes CORT a classic catalyst stock: huge potential reward, real downside if the story wobbles. For active traders, the setup is straightforward but not simple. Corcept Therapeutics has scheduled a clear event, highlighted its cortisol modulation focus, and spotlighted Korlym plus new launch Lifyorli. At the same time, multiple Form 4s - including the CFO's 40,000-share sale - remind everyone that insiders are locking in gains while the stock is elevated. As Tim Bohen, lead trainer with StocksToTrade says, "A good trade setup checks all the boxes - volume, trend, catalyst. Don't trade if you're missing pieces of the puzzle." In a name like CORT, where the catalyst is obvious and emotions can run high, respecting that checklist can help traders avoid chasing incomplete setups. The key now is preparation. Study the CORT chart, map support in the low-$90s and recent highs above $100, and plan scenarios for both a blowout and a disappointment. As Tim Sykes loves to say, "The market rewards prepared traders, not hopeful ones." Corcept Therapeutics is giving the market a big, tradable moment; it is on traders to manage risk, react to the numbers, and never confuse education and research with advice. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. One must-buy stock for Monday. Want to start next week off with a big win? Its new algorithm may have just uncovered a new dirt-cheap stock with a great chance of moving +100% or more this Monday. ...One ticker... ...One trade... ...One MONSTER move... All you have to do is make this one trade on Monday. While I can't promise future performance, previous picks from this new Monday Algo have racked up gains of +149%, +190%, and +536%... in as little as one day. And StocksToTrade, Inc. think this new pick could be just as big. But if StocksToTrade, Inc. is right, it may move FAST...

Corcept Therapeutics reported Q1 revenues of $164.9 million, up 4.9% year on year, but missed analysts' expectations by 11.3%. Despite the significant miss on earnings per share estimates, the stock has surged 107% since reporting and currently trades at $96.50, achieving the highest full-year guidance raise amongst its peers. The branded pharmaceuticals sector reported mixed Q1 results, with the 10 tracked stocks beating consensus revenue estimates by 3.6% on average. Share prices have risen 8.5% on average since earnings. Eli Lilly led the group with revenues of $19.8 billion, up 55.5% year on year, exceeding expectations by 13.7%. The stock has climbed 40.7% since reporting to $1,197.

Corcept Therapeutics Q2 earnings call highlights. July 29, 2026 Key points. * Second-quarter revenue rose 32% to $256.1 million, driven by growth in the Cushing's syndrome business and $47.6 million from newly launched ovarian cancer drug LIFYORLI. Corcept raised its 2026 revenue guidance to $1.1 billion-$1.2 billion. * LIFYORLI's launch is gaining traction, with more than 1,300 patients treated, over 1,000 prescribing physicians and coverage policies for more than 70% of relevant insured lives. Corcept expects the therapy's U.S. revenue in platinum-resistant ovarian cancer to eventually exceed $1 billion annually. * The FDA accepted Corcept's resubmitted relacorilant application for Cushing's syndrome and set a December 17, 2026, action date, while pipeline studies continue in cancer, MASH and ALS. * Five stocks we like better than Corcept Therapeutics. Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing's syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability. Net income rose to $43 million from $35 million a year earlier. Chief Financial Officer Atabak Mokari said operating expenses were flat compared with the first quarter, while cash and investments totaled $545 million as of June 30. The company raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion. Mokari said the updated outlook reflects strength in both Corcept's endocrinology and oncology businesses. LIFYORLI launch drives oncology growth. Corcept's LIFYORLI, approved by the FDA on March 25 for platinum-resistant ovarian cancer, generated $47.6 million in revenue after the company began selling the treatment April 1. Roberto Vieira, president of Corcept's oncology division, described the launch as one of the strongest for an oncology medication. Vieira said more than 1,300 patients have started treatment with LIFYORLI and more than 1,000 physicians have prescribed it to at least one patient. He said demand has come from academic and non-teaching hospitals as well as community oncology clinics. According to the company, more than 70% of combined Medicare, Medicaid and commercial insurance lives had formal coverage policies for LIFYORLI in place as of the call. The National Comprehensive Cancer Network listed the therapy as a preferred regimen 15 days after its approval, Corcept said. Vieira said the company continues to add patients weekly and is seeking to expand use among additional physicians and practices. He said Corcept expects LIFYORLI's U.S. annual revenue in platinum-resistant ovarian cancer alone to exceed $1 billion as adoption grows. In its pivotal ROSELLA study, LIFYORLI combined with nab-paclitaxel chemotherapy met both primary endpoints, according to Chief Executive Officer Joe Belanoff. He said the combination significantly delayed disease progression and extended overall survival compared with nab-paclitaxel alone. The company reported a 35% reduction in the risk of death, corresponding to a hazard ratio of 0.65 and a P value of 0.0004. Cushing's syndrome demand and relacorilant regulatory update. Korlym and authorized generic product revenue totaled $208.6 million during the quarter. Sean Maduck, president of Corcept's endocrinology division, said the company recorded a record number of new prescriptions, first-time prescribers and patients receiving its Cushing's syndrome medications. Discover more Derivatives Stock Screener Tool Maduck attributed growth to increased physician awareness of hypercortisolism, which can contribute to difficult-to-treat diabetes and resistant hypertension. He cited the company's CATALYST and MOMENTUM studies, which found hypercortisolism in portions of patients screened for those conditions. In response to analyst questions, Maduck said the specialty-pharmacy transition is behind the company and that second-quarter growth was not primarily driven by clearing a backlog. Rather, he said performance reflected continued service of existing patients and a record number of new enrollments. Belanoff said the FDA accepted Corcept's resubmitted new drug application for relacorilant in Cushing's syndrome and assigned a Prescription Drug User Fee Act date of Dec. 17, 2026. Corcept resubmitted the application June 17 after the FDA requested additional analyses of the data from the company's original application during an April meeting. The application is supported by the Phase III GRACE trial and evidence from the Phase III GRADIENT trial, a long-term extension study and earlier development work, Belanoff said. He said the company believes relacorilant demonstrated durable improvement in signs and symptoms of Cushing's syndrome without certain serious adverse events associated with currently approved medications. Pipeline studies continue across cancer, MASH and ALS. Corcept is evaluating relacorilant with chemotherapy in several solid tumors. Belanoff said one arm of the BELLA study in platinum-resistant ovarian cancer is expected to produce results this year, while additional BELLA arms in platinum-sensitive ovarian cancer and endometrial cancer, along with the STELLA cervical cancer trial and TRIDENT first-line pancreatic cancer trial, are expected to report results by the end of 2027. The company also initiated the Phase Ib SYNERGY study of nenicorilant with nivolumab across a range of solid tumors, with results expected by the end of next year. Outside oncology, Corcept said its 175-patient Phase IIb MONARCH study of miricorilant in metabolic dysfunction-associated steatohepatitis, or MASH, has completed enrollment and is expected to produce data later this year. Positive results could support advancement to Phase III, Belanoff said. For ALS, the company is conducting a dose-titration study of dazucorilant to improve gastrointestinal tolerability ahead of a planned pivotal trial expected to begin early next year. Belanoff cited Phase II DAZALS results showing reduced risk of death among patients receiving the 300-milligram dose, while noting that non-serious gastrointestinal distress accounted for most treatment discontinuations. About Corcept Therapeutics (NASDAQ:CORT). Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs. The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Corcept Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list. While Corcept Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.